Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.47 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.44 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.44 |
| ▸ | SSU72 | Q9NP77 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950037 | 0.83 | SMN1; SMN2 (0.60) | TACR1MAPTKDM4ESMN1; SMN2P2RX1 | |
| SCHEMBL5950236 | 0.81 | MEN1 (0.49) | MAPTKDM4ESMN1; SMN2FPR2MEN1 | |
| SCHEMBL31252452 | 0.77 | ULK1 (0.56) | ULK1TACR1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL6374689 | 0.77 | CNR1 (0.59) | SMN1; SMN2FPR2KMT2ATP53LMNA | |
| SCHEMBL6374146 | 0.77 | CNR1 (0.59) | SMN1; SMN2FPR2KMT2ATP53LMNA | |
| SCHEMBL5950200 | 0.75 | MEN1 (0.58) | MAPTFPR2MEN1KMT2ALMNA | |
| SCHEMBL5950360 | 0.75 | FPR2 (0.48) | SMN1; SMN2FPR2MEN1KMT2ALMNA | |
| SCHEMBL18620721 | 0.73 | HSD17B10 (0.66) | TACR1MAPTKDM4ESMN1; SMN2P2RX1 | |
| SCHEMBL2681462 | 0.73 | MAPT (0.78) | TACR1MAPTP2RX1ACP1MEN1 | |
| SCHEMBL2672092 | 0.72 | HDAC3 (0.41) | KDM4EMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | claimed |
| JP-2005538152-A | — | — | 2005-12-15 | — | — | JP | claimed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | claimed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | ULK1 3736/4885TACR1 399/4885MAPT 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.